Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Summary

This is a 128-week open-label study to assess the long-term safety and tolerabilty of the monoclonal antibody erenumab in migraine patients.

Timeline

Start

2019-09-30

Primary completion

2023-02-23

Completion

2023-03-13

Publications

• Gobel H, Schlegel E, Jaeger K, Ortler S, Leist L. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON). J Headache Pain. 2024 Sep 25;25(1):157. doi: 10.1186/s10194-024-01860-w.

Drugs

Indications